Iboga, ibogaine, noribogaine & 18-MC



Jump to:



Xu et al. (2000). A dose-response study of ibogaine-induced neuropathology in the rat cerebellum. Toxicological Sciences.

Zubaran, Shoaib & Stolerman (2000). The development and expression of locomotor sensitization to nicotine in the presence of ibogaine. Behavioural Pharmacology.

Alper (2001). Ibogaine: a review. The Alkaloids: Chemistry and Biology.

Alper, Beal & Kaplan (2001). A contemporary history of ibogaine in the United States and Europe. The Alkaloids: Chemistry and Biology.

Baumann et al. (2001). In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. The Journal of Pharmacology of Experimental Therapeutics.

Baumann et al. (2001). Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. The Alkaloids: Chemistry and Biology.

Binienda et al. (2001). Ibogaine neurotoxicity assessment: electrophysiological, neurochemical, and neurohistological methods. The Alkaloids: Chemistry and Biology.

Frenken (2001). From the roots up: ibogaine and addict self-help. The Alkaloids: Chemistry and Biology.

Glick et al. (2001). Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. The Alkaloids: Chemistry and Biology.

Helsley, Rabin & Winter (2001). Drug discrimination studies with ibogaine. The Alkaloids: Chemistry and Biology.

Leal et al. (2001). Ibogaine alters synaptosomal and glial glutamate release and uptake. NeuroReport.

Lotsof & Alexander (2001). Case studies of ibogaine treatment: implications for patient management strategies. The Alkaloids: Chemistry and Biology.

Mash et al. (2001). Ibogaine in the treatment of heroin withdrawal. The Alkaloids: Chemistry and Biology.

Onaivi, Akinshola & Ali (2001). Changes in gene expression and signal transduction following ibogaine treatment. The Alkaloids: Chemistry and Biology.

Kleber (2001). Ibogaine: proceedings of the First International Conference. The Alkaloids: Chemistry and Biology.

Parker & Siegel (2001). Modulation of the effects of rewarding drugs by ibogaine. The Alkaloids: Chemistry and Biology.

Popik & Wróbel (2001). Anxiogenic action of ibogaine. The Alkaloids: Chemistry and Biology.

Sershen, Hashim & Lajtha (2001). Characterization of multiple sites of action of ibogaine. The Alkaloids: Chemistry and Biology.

Skolnick (2001). Ibogaine as a glutamate antagonist: relevance to its putative antiaddictive properties. The Alkaloids: Chemistry and Biology.

Szumlinski et al. (2001). Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their antiaddictive properties. Pharmacology, Biochemistry and Behavior.

Szumlinski et al. (2001). Iboga interactions with psychomotor stimulants: panacea in the paradox? Toxicon.

Delorenzi et al. (2002). In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis. Antimicrobial Agents and Chemotherapy.

Jenks (2002). Extraction studies of Tabernanthe iboga and Voacanga africana. Natural Product Letters.

MacInnes & Handley (2002). Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine. British Journal of Pharmacology.

Onaivi et al. (2002). Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation. Annals of the New York Academy of Sciences.

Parke et al. (2002). Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine. Progress in Neuro-Psychopharmacology & Biological Psychiatry.

Zhang et al. (2002). Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. Drug Metabolism and Disposition.

Kuehne et al. (2003). Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. Journal of Medicinal Chemistry.

Leal et al. (2003). Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors. Progress in Neuro-Psychopharmacology & Biological Psychiatry.

Maisonneuve & Glick (2003). Anti-addictive actions of an iboga alkaloid congener: A novel mechanism for a novel treatment. Pharmacology, Biochemistry and Behavior.

Passarella et al. (2003). Ibogaine analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo[2.2.2]oct-7-enes. Bioorganic & Medicinal Chemistry.

Rezvani et al. (2003). Plant derivatives in the treatment of alcohol dependency. Pharmacology, Biochemistry and Behavior.

Wiley et al. (2003). Affinity and specificity of N-methyl-D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats. Psychopharmacology.

Hittner & Quello (2004). Combating substance abuse with ibogaine: pre- and posttreatment recommendations and an example of successive model fitting analyses. Journal of Psychoactive Drugs.

Kam et al. (2004). Cytotoxic effects and reversal of multidrug resistance by ibogan and related indole alkaloids. Bioorganic & Medicinal Chemistry Letters.

Kazlauskas et al. (2004). [Ibogaine--the substance for treatment of toxicomania. Neurochemical and pharmacological action]. Medicina.

Levant & Pazdernik (2004). Differential effects of ibogaine on local cerebral glucose utilization in drug-naive and morphine-dependent rats. Brain Research.

O’Hearn & Molliver (2004). Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine. Neuroscience.

Pace et al. (2004). Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. European Journal of Pharmacology.

Silva et al. (2004). Anti-HIV-1 activity of the Iboga alkaloid congener 18-methoxycoronaridine. Planta Medica.

He (2005). Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. The Journal of Neuroscience.

Kontrimaviciūte et al. (2005). Quantitation of ibogaine and 12-hydroxyibogamine in human plasma by liquid chromatography with fluorimetric detection. Journal of Chromatography

Panchal et al. (2005). Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. European Journal of Pharmacology.

Vastag (2005). Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'. Science.

Xu, Zheng & Sung (2005). Natural medicines for alcoholism treatment: A review. Drug and Alcohol Review.

Yordanov et al. (2005). Ibogaine reduces organ colonization in murine systemic and gastrointestinal Candida albicans infections. Journal of Medical Microbiology.

Alper & Glick (2006). Psychotropic complementary medicines. The British Journal of Psychiatry.

Bateman (2006). Ibogaine may help drug addicts live the 'never again'. South African Medical Journal.

Glick et al. (2006). 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. European Journal of Pharmacology.

He & Ron (2006). Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB Journal.

Kontrimaviciūte et al. (2006). Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root. Journal of Chromatography.

Kontrimaviciūte et al. (2006). Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub. Journal of Analytical Toxicology.